Key facts
- Fairmount Funds Management LLC filed SCHEDULE 13D/A for Viridian Therapeutics, Inc.\DE Common Stock, $0.01 par value per share (VRDN).
- Disclosed ownership: 14%.
- Date of event: 11 May 2026.
Fairmount Funds Management LLC - 11 May 2026 SCHEDULE 13D/A Report for Viridian Therapeutics, Inc.\DE Common Stock, $0.01 par value per share (VRDN)
- Filing Manager
- Fairmount Funds Management LLC
- Reporting Manager
- Fairmount Funds Management LLC
- Symbol
- VRDN
- Shares outstanding
- 122,519,943 shares
- Disclosed Ownership
- 17,201,800 shares
- Ownership
- 14%
- Form type
- SCHEDULE 13D/A
- Filing time
- 13 May 2026, 16:30:23 UTC
- Date of event
- 11 May 2026
- Previous filing
- 27 Oct 2025
- SEC
- View on sec.gov
Key filing fact
Fairmount Funds Management LLC disclosed 14% ownership in Viridian Therapeutics, Inc.\DE Common Stock, $0.01 par value per share (VRDN) on 11 May 2026.
Change
- Previous schedule filing date: 27 Oct 2025.
- Current filing was accepted on 13 May 2026, 16:30.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (2)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 14% | 17,201,800 | 0 | 17,201,800 | /s/ Peter Harwin | Peter Harwin, Managing Member | 0001802528 |
| Fairmount Healthcare Fund II GP LLC | 14% | 17,201,800 | 0 | 17,201,800 | /s/ Peter Harwin | Peter Harwin, Managing Member | 0001830382 |
CIK / CUSIP context first